Immunotherapy First for BRAF V600-Mutated Advanced Melanoma

Immunotherapy First for BRAF V600-Mutated Advanced Melanoma

Activating BRAF V600 mutations are present in around 50% of patients with advanced melanoma. Targeted therapy with combinations of BRAF/MEK inhibitors, such...

Sunitinib Effective for Malignant Pheochromocytoma/Paraganglioma

Sunitinib Effective for Malignant Pheochromocytoma/Paraganglioma

Pheochromocytomas and paragangliomas (PPs) are rare neuroendocrine tumors that arise from chromaffin cells in the adrenal medulla or extra-adrenal autonomic paraganglia, respectively....

FDA Approvals for Cancer Treatments in October 2021

FDA Approvals for Cancer Treatments in October 2021

The United States Food and Drug Administration (FDA) granted approvals to five therapeutic agents for the treatment of solid and hematologic cancers...

New Combinations Improve Survival in Prostate Cancer

New Combinations Improve Survival in Prostate Cancer

The treatment landscape of metastatic and non-metastatic prostate cancer is evolving rapidly. Practice-changing results from PEACE-1 and STAMPEDE clinical trials, which evaluated...

Benefit of First-Line Nivolumab Plus Chemo in Gastric/GEJ Cancers Sustained

Benefit of First-Line Nivolumab Plus Chemo in Gastric/GEJ Cancers Sustained

Gastric cancer (GC), including gastroesophageal junction cancer (GEJC), is a major health problem, and better treatments are needed to improve patient outcomes....

Pembrolizumab Beneficial for High-Risk Stage II Melanoma

Pembrolizumab Beneficial for High-Risk Stage II Melanoma

Adjuvant immunotherapy with PD-1 inhibitors (nivolumab or pembrolizumab) in resected stage III/IV melanoma reduces the risk of recurrence by approximately 40% and...